Journal Article Review Ppublish 18 citations
PubMed: 37971403 DOI: 10.1152/physrev.00015.2023
Phosphodiesterase in heart and vessels: from physiology to diseases.
Physiol Rev 104(2):765-834
Authors: Qin Fu, Ying Wang, Chen Yan, Yang K Xiang
Affiliations
- Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. The Key Laboratory for Drug Target Research and Pharmacodynamic Evaluation of Hubei Province, Wuhan, China.
- Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
- Aab Cardiovascular Research Institute, University of Rochester Medical Center, Rochester, New York, United States.
- Department of Pharmacology, University of California at Davis, Davis, California, United States.
- Department of Veterans Affairs Northern California Healthcare System, Mather, California, United States.
Abstract
Phosphodiesterases (PDEs) are a superfamily of enzymes that hydrolyze cyclic nucleotides, including cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Both cyclic nucleotides are critical secondary messengers in the neurohormonal regulation in the cardiovascular system. PDEs precisely control spatiotemporal subcellular distribution of cyclic nucleotides in a cell- and tissue-specific manner, playing critical roles in physiological responses to hormone stimulation in the heart and vessels. Dysregulation of PDEs has been linked to the development of several cardiovascular diseases, such as hypertension, aneurysm, atherosclerosis, arrhythmia, and heart failure. Targeting these enzymes has been proven effective in treating cardiovascular diseases and is an attractive and promising strategy for the development of new drugs. In this review, we discuss the current understanding of the complex regulation of PDE isoforms in cardiovascular function, highlighting the divergent and even opposing roles of PDE isoforms in different pathogenesis.
MeSH
Enzymes, Physiology, Nucleotides, Cyclic, Heart, Cardiovascular Diseases, Cells, Phosphoric Diester Hydrolases, Protein Isoforms
Cited by
- Inhibition of protein phosphatases attenuates A 1-adenosine receptor-stimulation induced negative inotropic effects of cAMP-increasing agents in the isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol, 2025
- Phosphodiesterase Inhibition and Immunotropic Activity of Dipyridamole Dynamic Derivatives. Curr Issues Mol Biol, 2025
- Integrative multi-omics analysis of metabolic dysregulation induced by occupational benzene exposure in mice. Sci Total Environ, 2025
- Phosphodiesterase Inhibitors in Fetal Growth Restriction: Do Not Forget to Consider Fetal Sex and Subcellular Compartmentation. Biomedicines, 2024
- Role of PDE4 Family in Cardiomyocyte Physiology and Heart Failure. Cells, 2025
- Promoting proteostasis by cAMP/PKA and cGMP/PKG. Trends Mol Med, 2025
- Targeting Phosphodiesterase 4 in Gastrointestinal and Liver Diseases: From Isoform-Specific Mechanisms to Precision Therapeutics. Biomedicines, 2025
- Glucagon Can Increase Force of Contraction via Glucagon Receptors in the Isolated Human Atrium. Int J Mol Sci, 2025
- Diverse Roles of the Multiple Phosphodiesterases in the Regulation of Cyclic Nucleotide Signaling in . Cells, 2025
- PDE3A as a Therapeutic Target for the Modulation of Compartmentalised Cyclic Nucleotide-Dependent Signalling. Cells, 2025
- Nanodomain cAMP signaling in cardiac pathophysiology: potential for developing targeted therapeutic interventions. Physiol Rev, 2025
- Phosphodiesterase 10A Inhibitor Modulates Right Ventricular Outflow Tract Electrophysiological Activities and Calcium Homeostasis via the cGMP/PKG Pathway. J Cell Mol Med, 2025
- Adenosine signaling: a potential therapeutic target for psychogenic erectile dysfunction. Am J Transl Res, 2025
- PDE4D inhibition ameliorates cardiac hypertrophy and heart failure by activating mitophagy. Redox Biol, 2025